Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection and plans to sell ‘substantially all’ of its assets. Coverage emphasizes the strategic value of Sangamo’s gene-editing technology, particularly its zinc-finger nuclease platform, which could bolster Lilly’s and Astellas’ pipelines.
Reports from *citybiz*, *Law360*, and *Fierce Biotech* note the move follows years of financial struggles and failed clinical trials, though Sangamo’s intellectual property remains a key draw. Next steps include formal auction processes and regulatory approvals for asset transfers.
Lilly and Astellas are expected to compete for Sangamo’s most advanced programs, with potential implications for the broader biotech and pharmaceutical sectors.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 18h ago.
Quick answers
Why is Sangamo selling its assets?
Sangamo filed for Chapter 11 bankruptcy and plans to sell ‘substantially all’ of its assets to address financial distress, as stated in coverage from *citybiz* and *Law360*.
Which companies are bidding for Sangamo’s assets?
Eli Lilly and Astellas Pharma are the two primary buyers identified in reports, with preliminary bids of up to $50 million each for specific assets, per *TradingView* and *BioSpace*.
What technology is Sangamo selling?
Coverage highlights Sangamo’s zinc-finger nuclease gene-editing platform as a key asset, which could enhance the pipelines of potential buyers like Lilly and Astellas.
Coverage (8)
- Sangamo Therapeutics, Inc. Filed for Bankruptcy marketscreener.com · 16h ago
- Lilly, Astellas bid on Sangamo's assets after bankruptcy filing FirstWord Pharma · 16h ago
- Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets The Business Journals · 16h ago
- Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection citybiz · 16h ago
- Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans Law360 · 16h ago
- Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas TradingView · 16h ago
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy BioSpace · 16h ago
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers Fierce Biotech · 16h ago
Topics
Related trends
Remember Korean Stealth Game MUDANG? Looks Like It's Not Coming Out
The stealth action game Mudang: Two Hearts has been officially cancelled following the bankruptcy of its developer, EVR Studio.
Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Public interest mounts as the White House addresses rumors linking Donald Trump to a single patient granted compassionate access to an experimental obesity drug.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s lung cancer drug fails pivotal trial, sending shockwaves through biotech markets
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
AbbVie’s $10.9B bid for Apogee Therapeutics signals a major shift in biotech’s immunology race
ROBERT F. KENNEDY JR.: The future of medicine should be built in America
Debate intensifies over U.S. reliance on Chinese biotechnology as policy experts and political figures weigh the future of domestic medical production.
Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
FDA reverses rejection of Regenxbio’s gene therapy for MPS II, signaling rare-disease drug approvals face new scrutiny